Attitudes toward medications for opioid use disorder among peer recovery specialists

References

• Cunningham C, Edlund MJ, Fishman M, Gordon AJ, Jones HE, Kampman KM, Langleben D, Meyer M, Springer S, Woody G, et al. The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update. J Addict Med. 2020;14:1.
   Web of Science ®Google Scholar
• Leshner AI, Mancher M, editors. Medications for opioid use disorder save lives. National Academy of Sciences; 2019.
   Google Scholar
• Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, Azocar F, Sanghavi DM. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3:e1920622. doi:10.1001/jamanetworkopen.2019.20622.
   PubMed Web of Science ®Google Scholar
• Lee JD, Nunes EV, Novo P, Bachrach K, Bailey GL, Bhatt S, Farkas S, Fishman M, Gauthier P, Hodgkins C, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X: BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391:309–18. doi:10.1016/S0140-6736(17)32812-X.
   PubMed Web of Science ®Google Scholar
• Jarvis BP, Holtyn AF, Subramaniam S, Tompkins DA, Oga EA, Bigelow GE, Silverman K. Extended-release injectable naltrexone for opioid use disorder: a systematic review. Addiction. 2018;113:1188–209. doi:10.1111/add.14180.
   PubMed Web of Science ®Google Scholar
• Burns M, Tang L, Chang CCH, Kim JY, Ahrens K, Allen L, Cunningham P, Gordon A, Jarlenski MP, Lanier P. Duration of medication treatment for opioid-use disorder and risk of overdose among medicaid enrollees in 11 states: a retrospective cohort study. Addiction. 2022;117:3079–88. doi:10.1111/add.15959.
   PubMed Web of Science ®Google Scholar
• Jones CM, Han B, Baldwin GT, Einstein EB, Compton WM. Use of medication for opioid use disorder among adults with past-year opioid use disorder in the US, 2021. JAMA Netw Open. 2023;6:e2327488. doi:10.1001/jamanetworkopen.2023.27488.
   PubMed Web of Science ®Google Scholar
• Madden EF, Prevedel S, Light T, Sulzer SH, Sulzer SH. Intervention stigma toward medications for opioid use disorder: a systematic review. CrimRxiv. 2021;1–20. doi:10.21428/cb6ab371.1848cb05.
   Google Scholar
• Pasman E. Reducing stigma toward medication for opioid use disorder through social work education, research, and practice. J Soc Work Pract Addict. 2022;22:86–92. doi:10.1080/1533256X.2022.2016339.
   Web of Science ®Google Scholar
• Mackey K, Veazie S, Anderson J, Bourne D, Peterson K. Barriers and facilitators to the use of medications for opioid use disorder: a rapid review. Journal Of General Internal Medicine. 2020;35:954–63. doi:10.1007/s11606-020-06257-4.
   PubMed Web of Science ®Google Scholar
• Randall-Kosich O, Andraka-Christou B, Totaram R, Alamo J, Nadig M. Comparing reasons for starting and stopping methadone, buprenorphine, and naltrexone treatment among a sample of white individuals with opioid use disorder. J Addict Med. 2020;14:e44. doi:10.1097/ADM.0000000000000584.
   PubMed Web of Science ®Google Scholar
• Uebelacker LA, Bailey G, Herman D, Anderson B, Stein M. Patients’ beliefs about medications are associated with stated preference for methadone, buprenorphine, naltrexone, or no medication-assisted therapy following inpatient opioid detoxification. J Subst Abuse Treat. 2016;66:48–53. doi:10.1016/j.jsat.2016.02.009.
   PubMed Web of Science ®Google Scholar
• Brown AR. Health professionals’ attitudes toward medications for opioid use disorder. Subst Abuse. 2022;43:598–614. doi:10.1080/08897077.2021.1975872.
   PubMed Web of Science ®Google Scholar
• Carl A, Pasman E, Broman MJ, Lister JJ, Agius E, Resko SM. Experiences of healthcare and substance use treatment provider-based stigma among patients receiving methadone. Drug Alcohol Depend Rep. 2023;6:100138. doi:10.1016/j.dadr.2023.100138.
   PubMedGoogle Scholar
• Winhusen T, Wilder C, Lyons MS, Theobald J, Kropp F, Lewis D. Evaluation of a personally-tailored opioid overdose prevention education and naloxone distribution intervention to promote harm reduction and treatment readiness in individuals actively using illicit opioids. Drug Alcohol Depend. 2020;216:108265. doi:10.1016/j.drugalcdep.2020.108265.
   PubMed Web of Science ®Google Scholar
• Johnson K, Jones C, Compton W, Baldwin G, Fan J, Mermin J, Bennett J. Federal response to the opioid crisis. Curr HIV/AIDS Rep. 2018;15:293–301. doi:10.1007/s11904-018-0398-8.
   PubMed Web of Science ®Google Scholar
• Gaiser MG, Buche JL, Wayment CC, Schoebel V, Smith JE, Chapman SA, Beck AJ. A systematic review of the roles and contributions of peer providers in the behavioral health workforce. Am J Prev Med. 2021;61:e203–10. doi:10.1016/j.amepre.2021.03.025.
   PubMed Web of Science ®Google Scholar
• Byrne KA, Roth PJ, Merchant K, Baginski B, Robinson K, Dumas K, Collie J, Ramsey B, Cull J, Cooper L, et al. Inpatient link to peer recovery coaching: results from a pilot randomized control trial. Drug Alcohol Depend. 2020;215:108234.
   PubMed Web of Science ®Google Scholar
• Scott CK, Grella CE, Nicholson L, Dennis ML. Opioid recovery initiation: pilot test of a peer outreach and modified recovery management checkup intervention for out-of-treatment opioid users. J Subst Abuse Treat. 2018;86:30–35. doi:10.1016/j.jsat.2017.12.007.
   PubMed Web of Science ®Google Scholar
• Paquette CE, Daughters SB, Witkiewitz K. Expanding the continuum of substance use disorder treatment: nonabstinence approaches. Clin Psychol Rev. 2022;91:102110. doi:10.1016/j.cpr.2021.102110.
   PubMed Web of Science ®Google Scholar
• Andraka-Christou B, Totaram R, Randall-Kosich O. Stigmatization of medications for opioid use disorder in 12-step support groups and participant responses. Subst Abuse. 2022;43:415–24. doi:10.1080/08897077.2021.1944957.
   PubMed Web of Science ®Google Scholar
• Gannon K, Pasman E. “Knowing or not knowing”: living as harm reductionists in twelve step recovery. J Subst Use Addict Treat [Internet]; 2023 Feb [accessed 2023 Jan 24]. 145. https://www.sciencedirect.com/science/article/pii/S2949875923000048.
   Google Scholar
• Krawczyk N, Negron T, Nieto M, Agus D, Fingerhood MI. Overcoming medication stigma in peer recovery: a new paradigm. Subst Abuse. 2018;39:404–09. doi:10.1080/08897077.2018.1439798.
   PubMed Web of Science ®Google Scholar
• Samuels EA, Bernstein SL, Marshall BDL, Krieger M, Baird J, Mello MJ. Peer navigation and take-home naloxone for opioid overdose emergency department patients: preliminary patient outcomes. J Subst Abuse Treat. 2018;94:29–34. doi:10.1016/j.jsat.2018.07.013.
   PubMed Web of Science ®Google Scholar
• Bergman BG, Ashford RD, Kelly JF. Attitudes toward opioid use disorder medications: results from a U.S. national study of individuals who resolved a substance use problem. Exp Clin Psychopharmacol. 2020;28:449–61. doi:10.1037/pha0000325.
   PubMed Web of Science ®Google Scholar
• Hoffman LA, Vilsaint CL, Kelly JF. Attitudes toward opioid use disorder pharmacotherapy among recovery community center attendees. J Subst Abuse Treat. 2021;131:108464. doi:10.1016/j.jsat.2021.108464.
   PubMed Web of Science ®Google Scholar
• Majer JM, Beasley C, Stecker E, Bobak TJ, Norris J, Nguyen HM, Ogata M, Siegel J, Isler B, Wiedbusch E, et al. Oxford house residents’ attitudes toward medication assisted treatment use in fellow residents. Community Ment Health J. 2018;54:571–77.
   PubMed Web of Science ®Google Scholar
• Aletraris L, Edmond MB, Paino M, Fields D, Roman PM. Counselor training and attitudes toward pharmacotherapies for opioid use disorder. Subst Abuse. 2016;37:47–53. doi:10.1080/08897077.2015.1062457.
   PubMed Web of Science ®Google Scholar
• Bride BE, Abraham AJ, Kintzle S, Roman PM. Social workers’ knowledge and perceptions of effectiveness and acceptability of medication assisted treatment of substance use disorders. Soc Work Health Care. 2013;52:43–58. doi:10.1080/00981389.2012.725457.
   PubMed Web of Science ®Google Scholar
• Madden EF. Intervention stigma: how medication-assisted treatment marginalizes patients and providers. Soc Sci Med. 2019;232:324–31. doi:10.1016/j.socscimed.2019.05.027.
   PubMed Web of Science ®Google Scholar
• Madden EF, Barker KK, Guerra J, Villanueva C, Sulzer SH. Variation in intervention stigma among medications for opioid use disorder. SSM - Qual Res Health. 2022;2:100161. doi:10.1016/j.ssmqr.2022.100161.
   Google Scholar
• Pasman E, Lee G, Kollin R, Rodriguez B, Agius E, Madden EF, Resko SM. Attitudes toward medication for opioid use disorder among substance use treatment providers. Subst Use Misuse. 2022;57:1828–36. doi:10.1080/10826084.2022.2115853.
   PubMed Web of Science ®Google Scholar
• Malvini Redden S, Tracy SJ, Shafer MS. A metaphor analysis of recovering substance abusers’ sensemaking of medication-assisted treatment. Qual Health Res. 2013;23:951–62. doi:10.1177/1049732313487802.
   PubMed Web of Science ®Google Scholar
• Woo J, Bhalerao A, Bawor M, Bhatt M, Dennis B, Mouravska N, Zielinski L, Samaan Z. “Don’t judge a book by its cover”: a qualitative study of methadone patients’ experiences of stigma. Subst Abuse Res Treat. 2017;11:117822181668508. doi:10.1177/1178221816685087.
   Web of Science ®Google Scholar
• Richard EL, Schalkoff CA, Piscalko HM, Brook DL, Sibley AL, Lancaster KE, Miller W, Go V. “You are not clean until you’re not on anything”: perceptions of medication-assisted treatment in rural Appalachia. Int J Drug Policy. 2020;85:102704. doi:10.1016/j.drugpo.2020.102704.
   PubMed Web of Science ®Google Scholar
• Suzuki J, Loguidice F, Martin B. Attitudes regarding medications for opioid use disorder among peer recovery coaches. J Addict Med. 2023;17:101–03. doi:10.1097/ADM.0000000000001025.
   PubMed Web of Science ®Google Scholar
• Pasman E, O’Shay S, Brown S, Madden EF, Agius E, Resko SM. Ambivalence and contingencies: A qualitative examination of peer recovery coaches’ attitudes toward medications for opioid use disorder. J Subst Use Addict Treat. 2023;155:209121. doi:10.1016/j.josat.2023.209121.
   PubMedGoogle Scholar
• Baldwin-White A. Psychological distress and substance abuse counselors: an exploratory pilot study of multiple dimensions of burnout. J Subst Use. 2016;21:29–34. doi:10.3109/14659891.2014.949316.
   Web of Science ®Google Scholar
• Davenport ES, Arnett SJ, Nichols MA, Miller ML. Indiana community pharmacist preceptors’ knowledge and perceptions of medication-assisted treatment. J Am Pharm Assoc. 2020;60:S20–28.4. doi:10.1016/j.japh.2020.01.001.
   Google Scholar
• Little RJA. A test of missing completely at random for multivariate data with missing values. J Am Stat Assoc. 1988;83:1198–202. doi:10.1080/01621459.1988.10478722.
   Web of Science ®Google Scholar
• Enders CK, Bandalos DL. The relative performance of full information maximum likelihood estimation for missing data in structural equation models. Struct Equ Model Multidiscip J. 2001;8:430–57. doi:10.1207/S15328007SEM0803_5.
   Web of Science ®Google Scholar
• Caplehorn JRM, Lumley TS, Irwig L. Staff attitudes and retention of patients in methadone maintenance programs. Drug Alcohol Depend. 1998;52:57–61. doi:10.1016/S0376-8716(98)00047-7.
   PubMed Web of Science ®Google Scholar
• Kayman DJ, Goldstein MF, Deren S, Rosenblum A. Predicting treatment retention with a brief “opinions about methadone” scale. J Psychoactive Drugs. 2006;38:93–100. doi:10.1080/02791072.2006.10399832.
   PubMed Web of Science ®Google Scholar
• Van Boekel LC, Brouwers EPM, van Weeghel J, Garretsen HFL. Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: systematic review. Drug Alcohol Depend. 2013;131:23–35. doi:10.1016/j.drugalcdep.2013.02.018.
   PubMed Web of Science ®Google Scholar
• Kropp F, Wilder C, Theobald J, Lewis D, Winhusen TJ. The feasibility and safety of training patients in opioid treatment to serve as peer recovery support service interventionists. Subst Abuse. 2022;43:527–30. doi:10.1080/08897077.2021.1949667.
   PubMed Web of Science ®Google Scholar
• Winhusen T, Wilder C, Kropp F, Theobald J, Lyons MS, Lewis D. A brief telephone-delivered peer intervention to encourage enrollment in medication for opioid use disorder in individuals surviving an opioid overdose: results from a randomized pilot trial. Drug Alcohol Depend. 2020;216:108270. doi:10.1016/j.drugalcdep.2020.108270.
   PubMed Web of Science ®Google Scholar
• Solomon P. Peer support/peer provided services underlying processes, benefits, and critical ingredients. Psychiatr Rehabil J. 2004;27:392–401. doi:10.2975/27.2004.392.401.
   PubMed Web of Science ®Google Scholar
• Alcoholics Anonymous [Internet]. 4th ed. New York City: Alcoholics Anonymous World Services, Inc.; 2001 [accessed 2022 Aug 24]. https://www.aa.org/the-big-book.
   Google Scholar
• D’Aniello C, Nguyen HN. Considerations for intentional use of self-disclosure for family therapists. J Fam Psychother. 2017;28:23–37. doi:10.1080/08975353.2017.1283147.
   Web of Science ®Google Scholar
• Knudsen HK, Ducharme LJ, Roman PM, Link T. Buprenorphine diffusion: the attitudes of substance abuse treatment counselors. J Subst Abuse Treat. 2005;29:95–106. doi:10.1016/j.jsat.2005.05.002.
   PubMed Web of Science ®Google Scholar
• Rieckmann TR, Kovas AE, McFarland BH, Abraham AJ. A multi-level analysis of counselor attitudes toward the use of buprenorphine in substance abuse treatment. Journal Of Substance Abuse Treatment. 2011;41:374–85. doi:10.1016/j.jsat.2011.05.005.
   PubMed Web of Science ®Google Scholar
• Bielenberg J, Swisher G, Lembke A, Haug NA. A systematic review of stigma interventions for providers who treat patients with substance use disorders. J Subst Abuse Treat. 2021;131:108486. doi:10.1016/j.jsat.2021.108486.
   PubMed Web of Science ®Google Scholar
• Bowes SM, Ammirati RJ, Costello TH, Basterfield C, Lilienfeld SO. Cognitive biases, heuristics, and logical fallacies in clinical practice: a brief field guide for practicing clinicians and supervisors. Prof Psychol Res Pract. 2020;51:435–45. doi:10.1037/pro0000309.
   Web of Science ®Google Scholar
• Vakharia S Talking about harm reduction [Internet]. Twitter. 2021. https://twitter.com/MyHarmReduction/status/1403775714600554505.
   Google Scholar
• Kennedy-Hendricks A, Barry CL, Gollust SE, Ensminger ME, Chisolm MS, McGinty EE. Social stigma toward persons with prescription opioid use disorder: associations with public support for punitive and public health-oriented policies. Psychiatr Serv. 2017;68:462–69. doi:10.1176/appi.ps.201600056.
   PubMed Web of Science ®Google Scholar
• McGinty EE, Barry CL, Stone EM, Niederdeppe J, Kennedy-Hendricks A, Linden S, Sherman SG. Public support for safe consumption sites and syringe services programs to combat the opioid epidemic. Prev Med. 2018;111:73–77. doi:10.1016/j.ypmed.2018.02.026.
   PubMed Web of Science ®Google Scholar
• Stone EM, Kennedy-Hendricks A, Barry CL, Bachhuber MA, McGinty EE. The role of stigma in U.S. primary care physicians’ treatment of opioid use disorder. Drug Alcohol Depend. 2021;221:108627. doi:10.1016/j.drugalcdep.2021.108627.
   PubMed Web of Science ®Google Scholar
• Lett E, Asabor E, Beltrán S, Cannon AM, Arah OA. Conceptualizing, contextualizing, and operationalizing race in quantitative health sciences research. Ann Fam Med. 2022;20:157–63. doi:10.1370/afm.2792.
   PubMed Web of Science ®Google Scholar
• Husain JM, Cromartie D, Fitzelle-Jones E, Brochier A, Borba CPC, Montalvo C. A qualitative analysis of barriers to opioid agonist treatment for racial/ethnic minoritized populations. J Subst Abuse Treat. 2023;144:108918. doi:10.1016/j.jsat.2022.108918.
   PubMed Web of Science ®Google Scholar
• Raz M. Treating addiction or reducing crime? Methadone maintenance and drug policy under the Nixon administration. J Policy Hist. 2017;29:58–86. doi:10.1017/S089803061600035X.
   Web of Science ®Google Scholar
• Andraka-Christou B. Addressing racial and ethnic disparities in the use of medications for opioid use disorder: study examines racial and ethnic disparities in the use of medications for opioid use disorder. Health Aff (Millwood). 2021;40:920–27. doi:10.1377/hlthaff.2020.02261.
   PubMed Web of Science ®Google Scholar
• Goedel WC, Shapiro A, Cerdá M, Tsai JW, Hadland SE, Marshall BDL. Association of racial/ethnic segregation with treatment capacity for opioid use disorder in counties in the United States. JAMA Netw Open. 2020;3:e203711. doi:10.1001/jamanetworkopen.2020.3711.
   PubMed Web of Science ®Google Scholar
• Khatri UG, Nguemeni Tiako MJ, Gebreyesus A, Reid A, Jacoby SF, South EC. “A lack of empathy:” a qualitative study of Black people seeking treatment for opioid use disorder. SSM - Qual Res Health. 2023;4:100298. doi:10.1016/j.ssmqr.2023.100298.
   Google Scholar
• Kariisa M, Davis NL, Kumar S, Seth P, Mattson CL, Chowdhury F, Jones CM. Vital signs: drug overdose deaths, by selected sociodemographic and social determinants of health characteristics — 25 states and the District of Columbia, 2019–2020. Morb Mortal Wkly Rep. 2022;71:940–47. doi:10.15585/mmwr.mm7129e2.
   PubMed Web of Science ®Google Scholar
• Smith TB, Trimble JE. Matching clients with therapists on the basis of race or ethnicity: a meta-analysis of clients’ level of participation in treatment. In: Foundations of multicultural psychology: research to inform effective practice. Washington, DC, US: American Psychological Association; 2016. pp. 115–28.
   Google Scholar
• Klein AA, Slaymaker VJ, Kelly JF. The 12 step affiliation and practices scale: development and initial validation of a measure assessing 12 step affiliation. Addict Behav. 2011;36:1045–51. doi:10.1016/j.addbeh.2011.06.011.
   PubMed Web of Science ®Google Scholar